Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Return on Assets (2022 - 2025)

Historic Return on Assets for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 0.26%.

  • ARS Pharmaceuticals' Return on Assets rose 100.0% to 0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.26%, marking a year-over-year increase of 100.0%. This contributed to the annual value of 0.03% for FY2024, which is 2400.0% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Return on Assets stood at 0.26% for Q3 2025, which was up 100.0% from 0.19% recorded in Q2 2025.
  • ARS Pharmaceuticals' Return on Assets' 5-year high stood at 0.01% during Q4 2024, with a 5-year trough of 0.29% in Q3 2023.
  • Its 4-year average for Return on Assets is 0.17%, with a median of 0.19% in 2025.
  • In the last 5 years, ARS Pharmaceuticals' Return on Assets plummeted by -2200bps in 2023 and then soared by 2700bps in 2024.
  • ARS Pharmaceuticals' Return on Assets (Quarter) stood at 0.13% in 2022, then crashed by -118bps to 0.28% in 2023, then surged by 96bps to 0.01% in 2024, then crashed by -2340bps to 0.26% in 2025.
  • Its Return on Assets was 0.26% in Q3 2025, compared to 0.19% in Q2 2025 and 0.08% in Q1 2025.